Advertisement

Esophagus

pp 1–12 | Cite as

Impact of tumor-infiltrating LAMP-3 dendritic cells on the prognosis of esophageal squamous cell carcinoma

  • Junya Nishimura
  • Hiroaki TanakaEmail author
  • Yoshihito Yamakoshi
  • Soichiro Hiramatsu
  • Tatsuro Tamura
  • Takahiro Toyokawa
  • Kazuya Muguruma
  • Kiyoshi Maeda
  • Kosei Hirakawa
  • Masaichi Ohira
Original Article
  • 10 Downloads

Abstract

Background

Dendritic cells (DCs) are the most potent antigen-presenting cells to induce cytotoxic T lymphocytes in the tumor environment. After acquiring antigens, DCs undergo maturation and their expression of MHC and co-stimulation molecules are enhanced, along with lysosome-associated membrane glycoprotein 3 (LAMP-3), which is a specific marker of mature DCs. In general, mature DCs are usually considered to be immunostimulatory in the cancer microenvironment. In addition, it is known that tumor-infiltrating lymphocytes (TILs) are associated with a good prognosis in esophageal squamous cell carcinoma (ESCC). However, few studies have targeted the interaction between DCs and TILs in the local immunity of ESCC. We investigated the localization of mature DCs within ESCC tissue and their relationship to TILs as well as the clinical outcome.

Methods

We evaluated 80 ESCC patients who underwent surgical treatment without preoperative treatment, using immunohistochemistry with LAMP-3 and CD8.

Results

The results showed that LAMP-3 DCs were predominantly observed in the peritumoral area. Intratumoral CD8 T cells were found to be associated with a favorable prognosis, and the number of infiltrating LAMP-3 DCs was correlated with the number of intratumoral CD8 T cells.

Conclusion

At the local tumor site, mature LAMP-3 DCs might be associated with increasing tumor infiltrating CD8 T cells.

Keywords

Esophageal Dendritic cell LAMP-3 

Notes

Compliance with ethical standards

Ethical statement

Our investigation was carried out according to the Declaration of Helsinki. All experimental procedures after 2013 were approved as no. 3138 by the Osaka City University ethics committee, and all patients had provided informed consent for collection and analysis of the specimens. On the other hand, because the other experimental procedures up to 2013 were only all-inclusive consent, we are showing opt-out form as an observational study.

Conflict of interest

All authors declare that there is no conflict of interest in the present study.

References

  1. 1.
    Ohashi S, Miyamoto S, Kikuchi O, et al. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology. 2015;149:1700–15.CrossRefGoogle Scholar
  2. 2.
    Kojima T, Doi T. Immunotherapy for esophageal squamous cell carcinoma. Curr Oncol Rep. 2017;19:017–0590.CrossRefGoogle Scholar
  3. 3.
    Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.  https://doi.org/10.1038/nrc3245.CrossRefGoogle Scholar
  4. 4.
    Zheng X, Song X, Shao Y, et al. Prognostic role of tumor-infiltrating lymphocytes in esophagus cancer: a meta-analysis. Cell Physiol Biochem. 2018;45:720–32.CrossRefGoogle Scholar
  5. 5.
    Sudo T, Nishida R, Kawahara A, et al. Clinical impact of tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma. Ann Surg Oncol. 2017;24:3763–70.CrossRefGoogle Scholar
  6. 6.
    Li J, Tang Y, Huang L, et al. A high number of stromal tumor-infiltrating lymphocytes is a favorable independent prognostic factor in M0 (stages I–III) esophageal squamous cell carcinoma. Dis Esophagus. 2017;30:1–7.CrossRefGoogle Scholar
  7. 7.
    Lill PH, Fortner GW. Identification and cytotoxic reactivity of inflammatory cells recovered from progressing or regressing syngeneic UV-induced murine tumors. J Immunol. 1978;121:1854–60.Google Scholar
  8. 8.
    Pepper M, Jenkins MK. Origins of CD4(+) effector and central memory T cells. Nat Immunol. 2011;12:467–71.CrossRefGoogle Scholar
  9. 9.
    Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity. 2014;40:642–56.CrossRefGoogle Scholar
  10. 10.
    Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 2016;37:855–65.CrossRefGoogle Scholar
  11. 11.
    de Saint-Vis B, Vincent J, Vandenabeele S, et al. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity. 1998;9:325–36.CrossRefGoogle Scholar
  12. 12.
    Barois N, de Saint-Vis B, Lebecque S, et al. MHC class II compartments in human dendritic cells undergo profound structural changes upon activation. Traffic. 2002;3:894–905.CrossRefGoogle Scholar
  13. 13.
    Karthaus N, Torensma R, Tel J. Deciphering the message broadcast by tumor-infiltrating dendritic cells. Am J Pathol. 2012;181:733–42.CrossRefGoogle Scholar
  14. 14.
    Ladanyi A, Kiss J, Somlai B, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 2007;56:1459–69.CrossRefGoogle Scholar
  15. 15.
    Sandel MH, Dadabayev AR, Menon AG, et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res. 2005;11:2576–82.CrossRefGoogle Scholar
  16. 16.
    Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med. 1999;190:1417–26.CrossRefGoogle Scholar
  17. 17.
    Treilleux I, Blay JY, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004;10:7466–74.CrossRefGoogle Scholar
  18. 18.
    Nagorsen D, Voigt S, Berg E, et al. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med. 2007;5:1479–5876.CrossRefGoogle Scholar
  19. 19.
    Liu J, Lu G, Li Z, et al. Distinct compartmental distribution of mature and immature dendritic cells in esophageal squamous cell carcinoma. Pathol Res Pract. 2010;206:602–6.CrossRefGoogle Scholar
  20. 20.
    Ishigami S, Ueno S, Matsumoto M, et al. Prognostic value of CD208-positive cell infiltration in gastric cancer. Cancer Immunol Immunother. 2010;59:389–95.CrossRefGoogle Scholar
  21. 21.
    Japan Esophageal S. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.CrossRefGoogle Scholar
  22. 22.
    Richards CH, Roxburgh CS, Powell AG, et al. The clinical utility of the local inflammatory response in colorectal cancer. Eur J Cancer. 2014;50:309–19.CrossRefGoogle Scholar
  23. 23.
    Iwamoto M, Shinohara H, Miyamoto A, et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer. 2003;104:92–7.CrossRefGoogle Scholar
  24. 24.
    Shurin GV, Ma Y, Shurin MR. Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenviron. 2013;6:159–67.CrossRefGoogle Scholar
  25. 25.
    Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature. 2004;427:154–9.CrossRefGoogle Scholar
  26. 26.
    Suzuki A, Masuda A, Nagata H, et al. Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J Pathol. 2002;196:37–433.CrossRefGoogle Scholar
  27. 27.
    Ahn S, Cho J, Sung J, et al. The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biol. 2012;33:1573–80.CrossRefGoogle Scholar
  28. 28.
    Johnson LA, Jackson DG. Control of dendritic cell trafficking in lymphatics by chemokines. Angiogenesis. 2014;17:335–45.CrossRefGoogle Scholar

Copyright information

© The Japan Esophageal Society and Springer 2019

Authors and Affiliations

  • Junya Nishimura
    • 1
  • Hiroaki Tanaka
    • 1
    Email author
  • Yoshihito Yamakoshi
    • 1
  • Soichiro Hiramatsu
    • 1
  • Tatsuro Tamura
    • 1
  • Takahiro Toyokawa
    • 1
  • Kazuya Muguruma
    • 1
  • Kiyoshi Maeda
    • 1
  • Kosei Hirakawa
    • 1
  • Masaichi Ohira
    • 1
  1. 1.Department of Surgical OncologyOsaka City University Graduate School of MedicineOsakaJapan

Personalised recommendations